Sign in
Taking people in United KingdomNo phase

Studies how polycystic ovary syndrome affects metabolism in women

Observes women with polycystic ovary syndrome to find who has higher metabolic risk.

Key facts

Who runs it
Imperial College London
Where
Birmingham, United KingdomSee the site
Trial code
Registry title
DAISy-PCOS Phenome Study - Dissecting Androgen Excess and Metabolic Dysfunction in Polycystic Ovary Syndrome
Status
Recruiting
People taking part
1,000 people, planned
Started
14 Aug 2019
Expected to end
1 Dec 2027
Type of study
Observational
Treatments tested
  • Women with polycystic ovary syndrome
Record updated
5 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 18-70 years with a suspected diagnosis of polycystic ovary syndrome (PCOS). It studies hormones and metabolism to find who is at the highest risk of metabolic disease.

Age
18-70 years
Sex
Women only
Disease stage
Suspected diagnosis of polycystic ovary syndrome
Earlier treatment
Cannot have used glucocorticoids in the last six months. Cannot have used drugs that affect steroid or metabolic function in the last six months. Cannot have used oral or transdermal hormonal contraception in the last three months. Cannot have used contraceptive implants in the last twelve months. Cannot have been in another trial of an investigational medicine in the last 12 weeks.

Main reasons for not taking part

  • Pregnant or breastfeeding at the time of planned recruitment
  • Significant kidney impairment (eGFR<30) or liver impairment
  • Any other significant disease that could put the participant at risk or affect the study results
  • Taking part in another trial of an investigational medicine in the last 12 weeks
  • Not able to give informed consent

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Women with a suspected diagnosis of polycystic ovary syndrome
  • Age range 18-70 years
  • Ability to provide informed consent

Who cannot take part

  • Current intake of drugs known to impact upon steroid or metabolic function or intake of such drugs during the six months preceding the planned recruitment
  • Use of contraceptive implants in the twelve months preceding the planned recruitment
  • Any other significant disease or disorder that, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study
  • History of significant renal (eGFR<30) or hepatic impairment (AST or ALT >two-fold above ULN; pre-existing bilirubinaemia >1.2 ULN)
  • Pregnancy or breastfeeding at the time of planned recruitment
  • Participants who have participated in another research study involving an investigational medicinal product in the 12 weeks preceding the planned recruitment
  • Glucocorticoid use via any route within the last six months
  • Use of oral or transdermal hormonal contraception in the three months preceding the planned recruitment

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United Kingdom

  • Wellcome Trust Clinical Research FacilityBirmingham, United KingdomContact: Eka MelsonTaking people

About the trial

What the trial wants to find out

Polycystic ovary syndrome (PCOS) affects 10% of all women and usually presents with irregular menstrual periods and difficulties conceiving. However, PCOS is also a lifelong metabolic disorder and affected women have an increased risk of type 2 diabetes, high blood pressure, and heart disease. Increased blood levels of male hormones, also termed androgens, are found in most PCOS patients. Androgen excess appears to impair the ability of the body to respond to the sugar-regulating hormone insulin (=insulin resistance). The investigator has found that fat tissue of PCOS patients overproduces androgens and that this can result in a build-up of toxic fat, which increases insulin resistance and could cause liver damage. In a large cohort of women registered in a GP database, the study team have found that androgen excess increases the risk of fatty liver disease. The aim is to identify those women with PCOS who are at the highest risk of developing metabolic disease, which would allow for early detection and potentially prevention of type 2 diabetes, high blood pressure, fatty liver and cardiovascular disease. The investigator will assess clinical presentation, androgen production and metabolic function in women with PCOS to use similarities and differences in these parameters for the identification of subsets (=clusters) of women who are at the highest risk of metabolic disease. The investigator will do this by using a standardised set of questions to scope PCOS-related signs and symptoms and the patient's medical history and measure body composition and blood pressure. This standardised recording of a patient's clinical presentation (=clinical phenotype) is called Phenome analysis. The investigator will collect blood and urine samples for the systematic measurement of steroid hormones including a very detailed androgen profile (=steroid metabolome analysis) and of thousands of substances produced by human metabolism (=global metabolome analysis). Phenome and metabolome data will then undergo integrated computational analysis for the detection of clusters predictive of metabolic risk.

Treatments tested

  • Women with polycystic ovary syndrome

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Dissecting Androgen Excess and Metabolic Dysfunction for an Integrated Systems Approach to Polycystic Ovary Syndrome Through the Assessment of Detailed Phenome and Metabolome Data
Plain-language title
Studies how polycystic ovary syndrome affects metabolism in womenGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT03911297, who can take part
Record updated
5 December 2024